Spirometry is a commonly performed assessment of lung function for diagnostic purposes as well as for monitoring of chronic lung diseases. The last international standardization of this technique was published in 2005. After 14 years, a group of experts from two leading scientific societies, American Thoracic Society (ATS) and European Respiratory Society (ERS), published a joint position that updated the standardization of spirometry, with an extensive criteria re-organization, including key updates such as: relative contraindications, instrumentation requirement to meet the International Organization for Standardization (ISO) standards, quality assurance, operator training, pre-test requirements, acceptability and usability criteria. New standards underline three key elements to obtain high quality pulmonary function data: an accurate and precise instrumentation, a patient/subject capable of performing acceptable and repeatable measurements, and a motivated technologist to elicit maximum performance from the patient. Never- theless, although COVID-19 pandemic has enormously impacted and limited a widespread application of spirometry, it has prompted much attention on hygienic procedures and on further research on noncontact spirometers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095332 | PMC |
http://dx.doi.org/10.23749/mdl.v112i2.11420 | DOI Listing |
J Infect Dev Ctries
December 2024
Department of Radiology, University of Health Sciences, Bursa Faculty of Medicine, City Training and Research Hospital, Bursa, Turkey.
Introduction: We aimed to present the changes that may occur in pulmonary functions in children who experienced more severe coronavirus disease 2019 (COVID-19) during long-term follow-up.
Methodology: A prospective longitudinal observational cohort study was conducted with 34 pediatric patients (7-18 years) who were hospitalized with COVID-19 infection (moderate n = 25, severe n = 9), and followed up at our Pediatric Infection Outpatient Clinic for approximately two years. Pulmonary function tests (PFTs) were performed using spirometry.
Life (Basel)
January 2025
Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with a median survival of 3-5 years. Antifibrotic therapies like pirfenidone and nintedanib slow progression, but the outcomes vary. Gender may influence disease presentation, progression, and response to treatment.
View Article and Find Full Text PDFBMC Anesthesiol
January 2025
Ankara Training and Research Hospital, Cardiovascular Surgery Clinic, Ankara, Turkey.
Background: Incentive spirometer is used in lung expansion therapy to maintain alveolar patency and improve pulmonary volumes in postoperative cardiac surgical patients. Deep breathing exercises with an incentive spirometer significantly reduce the development of postoperative pulmonary complications after open-heart cardiac surgery.
Aim: To determine the effect of deep breathing exercises with an incentive spirometer initiated in the preoperative period on respiratory parameters and complications in patients who underwent open-heart surgery.
In recent years, our clinical practice as paediatric pulmonologists has focused on refining strategies to optimise pulmonary function tests (PFTs) for preschool children, particularly those aged as young as 2 years and 5 months. This viewpoint reflects on our experience conducting over 7000 spirometry and impulse oscillometry (IOS) tests, sharing practical insights into achieving high success rates with young children. We emphasise the importance of creating a child-friendly, minimally stimulating environment, tailored communication using familiar and engaging language, and leveraging gamification and positive reinforcement.
View Article and Find Full Text PDFChron Respir Dis
January 2025
The Woolcock Institute of Medical Research, The University of Sydney, Sydney, Australia.
Individuals with Preserved Ratio Impaired Spirometry (PRISm), defined as FEV/FVC ≥0.7 and FEV1 <80% predicted, are at higher risk of developing COPD. However, data for Australian adults are limited.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!